CHRNA1 (Cholinergic Receptor Nicotinic Alpha Subunit 1) encodes the alpha-1 subunit of the nicotinic acetylcholine receptor (nAChR), a ligand-gated ion channel critical for neuromuscular junction (NMJ) formation and function. Mutations in CHRNA1 cause congenital myasthenic syndromes and are implicated in various neurological conditions.
| Property | Value |
|----------|-------|
| **Gene Symbol** | CHRNA1 |
| **Full Name** | Cholinergic Receptor Nicotinic Alpha Subunit 1 |
| **Chromosomal Location** | 2q31.1 |
| **NCBI Gene ID** | 1135 |
| **OMIM** | 100710 |
| **Ensembl** | ENSG00000138435 |
| **UniProt** | P30530 |
| **Associated Diseases** | Congenital myasthenic syndrome, myasthenia gravis, neuromuscular junction disorders |
CHRNA1 is a human gene whose product cHRNA1 is a key component of the muscle-type nAChR, a pentameric ligand-gated ion channel:. Variants in CHRNA1 have been implicated in Neuromuscular Disorders, Neurodegeneration. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
CHRNA1 is a key component of the muscle-type nAChR, a pentameric ligand-gated ion channel:
- ACh Binding: The alpha-1 subunit contains the primary acetylcholine binding site
- Ion Channel: Forms the cation-permeable pore for Na⁺ and K⁺ influx
- Endplate Potential: Triggers muscle fiber depolarization at the NMJ
- Pentameric Assembly: Typically (α1)₂β1δ1ε1 in adult receptors
- Developmental Isoforms: Embryonic receptors contain γ instead of ε subunit
- Fast Synaptic Transmission: Millisecond-scale channel opening for rapid signaling
- Synaptic Differentiation: Essential for postsynaptic specialization
- Rapsyn Clustering: Partners with rapsyn for receptor anchoring
- Agrin-LRP4-MuSK: Downstream of the agrin signaling pathway
- Congenital Myasthenic Syndrome (CMS): Over 100 mutations in CHRNA1 cause CMS
- Myasthenia Gravis: Autoantibodies target nAChR including the alpha-1 subunit
- Slow Channel Syndrome: Gain-of-function mutations cause prolonged channel opening
- ALS: Altered nAChR expression in motor neurons
- Alzheimer's Disease: Neuronal nAChRs (α4β2, α7) are affected; muscle nAChR changes less studied
- Peripheral Neuropathy: Chemotherapy-induced neuropathy involves nAChR dysfunction
CHRNA1 is primarily expressed in:
- Skeletal Muscle: Highest expression in extraocular, limb, and trunk muscles
- Neuromuscular Junctions: Concentrated at the motor endplate
- Low/Restricted: Minimal expression in CNS neurons
- Nicotinic Agonists: Nicotine and derivatives for cognitive enhancement
- Antagonists: Curare and derivatives for anesthesia
- Allosteric Modulators: Positive allosteric modulators in development
- Gene therapy for CMS
- Understanding nAChR dysfunction in neurodegenerative diseases